An interventional study of aspirin, clopidogrel, cilostazol, and dipyridamole in Acute Ischemic Stroke and Thrombocytopenia, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-18.
Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Prevention
The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
Antiplatelet therapy is widely used in non-cardiogenic AIS patients for secondary prevention. However, it may also increase the risk of bleeding complications, especially in patients with thrombocytopenia. The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
2,593 studies on the registry are indexed under Ischemic Stroke; 930 are open to participants now.
This study's planned enrollment of 1,200 is above the median of 120 across 1,752 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,058 studies on the registry; 511 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
Drug: aspirin, clopidogrel, cilostazol, and dipyridamole
Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
Also known as: Antiplatelet Agents
90-day Composite events
Composite events including ischemic stroke, hemorrhagic stroke, myocardial infarction, major extracranial hemorrhage, and vascular death within 90 days after enrollment
Time frame: 90 days
90-day ischemic stroke
Ischemic stroke within 90 days after enrollment
Time frame: 90 days
90-day hemorrhagic stroke
Hemorrhagic stroke within 90 days after enrollment
Time frame: 90 days
90-day myocardial infarction
Myocardial infarction within 90 days after enrollment
Time frame: 90 days
90-day major extracranial hemorrhage
Major extracranial hemorrhage within 90 days after enrollment
Time frame: 90 days
90-day non-major bleeding
Non-major bleeding within 90 days after enrollment
Time frame: 90 days
90-day vascular death
Vascular death within 90 days after enrollment
Time frame: 90 days
90-day all-cause death
All-cause death within 90 days after enrollment
Time frame: 90 days
Discharge mRS
Modified Rankin scale at discharge
Time frame: Through hospitalization, an average of 7 days
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, School of Medicine, Zhejiang University